Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 16, 2009

PGxHealth Introduces Molecular Diagnostic for Dilated Cardiomyopathy

  • PGxHealth reports that its genetic test for familial dilated cardiomyopathy, Familion® DCM (dilated cardiomyopathy) Test, is now available. The diagnostic will help clinicians detect familial DCM, interpret borderline clinical findings, and identify at-risk family members creating the opportunity for early intervention.

    It sequences 12 genes (LMNA, ANKRD1, TNNC1, SCN5A, TPM1, MYBPC3, ACT1, LDB3, PLN, MYH7, TNNT2, and TNNI3) and is performed in a CLIA-certified commercial laboratory that meets all applicable state and federal guidelines. In particular, the Familion DCM Test is the only DCM panel to include SCN5A and ANKRD1, which account for 5% of gene mutations in familial DCM patients, Clinical Data, PGx’ parent company explains.

    The DCM Test expands the Familion group of genetic tests to six tests used to diagnose or confirm familial heart disease. These diagnostics detect mutations that can cause cardiac channelopathies and cardiomyopathies, including long QT syndrome, Brugada syndrome catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy.

    PGxHealth also has a companion diagnostic for follicular lymphoma treatment rituximab called, PGxPredict:Rituximab. It identifies patients who are homozygous for the 158V isoform of FCGR3A, as studies have shown that they achieve significantly higher response rates to rituximab.


Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »